PL4157832T3 - Sól i postacie krystaliczne agonistów GLP-1R oraz ich zastosowania - Google Patents
Sól i postacie krystaliczne agonistów GLP-1R oraz ich zastosowaniaInfo
- Publication number
- PL4157832T3 PL4157832T3 PL21733318.6T PL21733318T PL4157832T3 PL 4157832 T3 PL4157832 T3 PL 4157832T3 PL 21733318 T PL21733318 T PL 21733318T PL 4157832 T3 PL4157832 T3 PL 4157832T3
- Authority
- PL
- Poland
- Prior art keywords
- glp
- agonists
- salt
- crystal forms
- crystal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/22—Tricarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020092530 | 2020-05-27 | ||
| PCT/US2021/034191 WO2021242817A1 (en) | 2020-05-27 | 2021-05-26 | Salt and crystal forms of glp-1r agonists and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4157832T3 true PL4157832T3 (pl) | 2024-12-16 |
Family
ID=76502864
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21733318.6T PL4157832T3 (pl) | 2020-05-27 | 2021-05-26 | Sól i postacie krystaliczne agonistów GLP-1R oraz ich zastosowania |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230203023A1 (pl) |
| EP (1) | EP4157832B1 (pl) |
| JP (1) | JP7702973B2 (pl) |
| CN (1) | CN115867546B (pl) |
| AU (1) | AU2021281237A1 (pl) |
| CA (1) | CA3179890A1 (pl) |
| DK (1) | DK4157832T3 (pl) |
| ES (1) | ES2985435T3 (pl) |
| FI (1) | FI4157832T3 (pl) |
| HU (1) | HUE068535T2 (pl) |
| PL (1) | PL4157832T3 (pl) |
| PT (1) | PT4157832T (pl) |
| WO (1) | WO2021242817A1 (pl) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA54555A (fr) * | 2018-11-22 | 2021-09-29 | Qilu Regor Therapeutics Inc | Agonistes de glp-1r et leurs utilisations |
| CN114630823B (zh) | 2019-10-25 | 2025-01-28 | 吉利德科学公司 | Glp-1r调节化合物 |
| EP4523751A3 (en) | 2020-01-29 | 2025-05-28 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| US11851419B2 (en) | 2020-11-20 | 2023-12-26 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
| EP4304711A1 (en) | 2021-03-11 | 2024-01-17 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| WO2022192430A1 (en) | 2021-03-11 | 2022-09-15 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| JP7772778B2 (ja) | 2021-03-24 | 2025-11-18 | 塩野義製薬株式会社 | 縮合環を有するｇｌｐ－１受容体作動薬を含有する医薬組成物 |
| DK4271672T3 (da) | 2021-04-21 | 2026-02-16 | Gilead Sciences Inc | Carboxy-benzimidazol glp-1r-modulerende forbindelser |
| EP4353717A4 (en) | 2021-08-30 | 2025-01-15 | Mindrank AI Ltd. | Novel aryl ether substituted heterocyclic compound as glp1r agonist |
| AU2022344074A1 (en) | 2021-09-08 | 2024-02-29 | Shionogi & Co., Ltd. | Medicine for prevention and treatment of diseases linked to anti-obesity activity |
| PL4408840T3 (pl) | 2021-09-27 | 2025-12-22 | Terns Pharmaceuticals, Inc. | Kwasy benzoimidazolokarboksylowe jako agoniści glp-1r |
| IL312364A (en) | 2021-10-25 | 2024-06-01 | Luehr Gary W | Compounds as GLP-1R agonists |
| KR20240125004A (ko) * | 2021-12-23 | 2024-08-19 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | Glp-1 수용체 작용제의 결정 형태 및 이의 제조방법 |
| IL315151A (en) | 2022-02-23 | 2024-10-01 | Terns Pharmaceuticals Inc | Compounds as glp-1r agonists |
| CN117362282A (zh) * | 2022-07-07 | 2024-01-09 | 杭州德睿智药科技有限公司 | Glp-1r激动剂的盐及其制备方法和应用 |
| EP4559910A1 (en) * | 2022-07-18 | 2025-05-28 | Minidrank Therapeutics (Suzhou) New Drug Research and Development Co., Ltd | Polymorphic form of glp-1r agonist, preparation method therefor and use thereof |
| JPWO2024063143A1 (pl) | 2022-09-22 | 2024-03-28 | ||
| TW202506131A (zh) | 2023-04-07 | 2025-02-16 | 美商拓臻製藥公司 | ＧＬＰ－１Ｒ及ＴＨＲβ激動劑之組合以及其使用方法 |
| WO2025057134A2 (en) | 2023-09-14 | 2025-03-20 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| US12291530B1 (en) | 2023-11-24 | 2025-05-06 | Ascletis Pharma (China) Co., Limited | GLP-1R agonist and therapeutic method thereof |
| WO2025158275A1 (en) | 2024-01-24 | 2025-07-31 | Pfizer Inc. | Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| MX387259B (es) | 2016-12-16 | 2025-03-18 | Pfizer | Agonistas receptores de glp-1 y usos de los mismos |
| MA54555A (fr) * | 2018-11-22 | 2021-09-29 | Qilu Regor Therapeutics Inc | Agonistes de glp-1r et leurs utilisations |
| TW202144340A (zh) * | 2020-04-03 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用 |
| CN111978313B (zh) * | 2020-08-28 | 2022-01-18 | 深圳大学 | 具备聚集诱导发光性质的多模态光诊疗剂及其制备与应用 |
-
2021
- 2021-05-26 PL PL21733318.6T patent/PL4157832T3/pl unknown
- 2021-05-26 FI FIEP21733318.6T patent/FI4157832T3/fi active
- 2021-05-26 ES ES21733318T patent/ES2985435T3/es active Active
- 2021-05-26 WO PCT/US2021/034191 patent/WO2021242817A1/en not_active Ceased
- 2021-05-26 DK DK21733318.6T patent/DK4157832T3/da active
- 2021-05-26 CA CA3179890A patent/CA3179890A1/en active Pending
- 2021-05-26 US US17/927,502 patent/US20230203023A1/en active Pending
- 2021-05-26 PT PT217333186T patent/PT4157832T/pt unknown
- 2021-05-26 CN CN202180041199.0A patent/CN115867546B/zh active Active
- 2021-05-26 HU HUE21733318A patent/HUE068535T2/hu unknown
- 2021-05-26 EP EP21733318.6A patent/EP4157832B1/en active Active
- 2021-05-26 AU AU2021281237A patent/AU2021281237A1/en active Pending
- 2021-05-26 JP JP2022572686A patent/JP7702973B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021281237A1 (en) | 2023-01-19 |
| JP7702973B2 (ja) | 2025-07-04 |
| EP4157832A1 (en) | 2023-04-05 |
| DK4157832T3 (da) | 2024-09-23 |
| CN115867546B (zh) | 2024-10-18 |
| WO2021242817A1 (en) | 2021-12-02 |
| HUE068535T2 (hu) | 2025-01-28 |
| ES2985435T3 (es) | 2024-11-05 |
| JP2023527997A (ja) | 2023-07-03 |
| FI4157832T3 (fi) | 2024-08-29 |
| PT4157832T (pt) | 2024-07-30 |
| US20230203023A1 (en) | 2023-06-29 |
| TW202210473A (zh) | 2022-03-16 |
| EP4157832B1 (en) | 2024-06-19 |
| CA3179890A1 (en) | 2021-12-02 |
| CN115867546A (zh) | 2023-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT4157832T (pt) | Formas de sal e cristal de agonistas de glp-1r e utilizações dos mesmos | |
| EP4228753C0 (en) | CRYSTALLINE FORMS OF GLP-1 R AGONISTS AND THEIR USES | |
| IL287472A (en) | Crystalline form of wee1 inhibitory compound and use thereof | |
| SG11202110825WA (en) | Glp-1r agonists and uses thereof | |
| ZA202007037B (en) | Crystal form of c-met inhibitor and salt form thereof and preparation method therefor | |
| SG11202109438TA (en) | A salt and crystal form of a fak inhibitor | |
| IL277326A (en) | Polymorphs of calcium salts that suppress dihydroureoate dehydrogenase, and methods for their production | |
| SG11202001153RA (en) | Leucoindigo salt solution with very low content of aniline and method of making same | |
| IL292499A (en) | compressed siglec-9 ecd molecules and methods of using them | |
| IL288348A (en) | A method for the synthesis of a furoimidazopyridine compound, a crystalline form of a furoimidazopyridine compound, and a crystalline form of its salt | |
| ZA202003581B (en) | Crystal form of urat1 inhibitor, and preparation method therefor | |
| PT3725786T (pt) | Forma cristalina e forma salina de inibidor de tgf-bri e método de preparação das mesmas | |
| IL308804A (en) | TREM2 agonistic biomarkers and methods of using them | |
| EP4249476A4 (en) | Salt of a benzothiazole compound, crystal form and use thereof | |
| PT3725791T (pt) | Sal que serve como inibidor de akt e seu cristal | |
| ZA202101589B (en) | Crystal form of tri-cycle compound and application thereof | |
| EP3901149A4 (en) | IMPURITIES OF AMIDE DERIVATIVES AND THEIR USE | |
| PT3441430T (pt) | Solução de sal de leucoíndigo com muito baixo conteúdo de anilina e método de fabrico | |
| EP4438606A4 (en) | NEW CRYSTALLINE FORM OF A NUCLEOSIDE COMPOUND AND ITS SALT | |
| EP3498704A4 (en) | LONG-ACTING DPP-IV INHIBITOR CRYSTAL AND ITS SALT | |
| GB2571229B (en) | Additives to reduce the crystallization temperature of brines and methods of use | |
| IL274274A (en) | Salt form and crystal form of compound as FGFR4 inhibitor and method of their preparation | |
| PT3441431T (pt) | Métodos de fabrico de soluções de sal leucoindigo com teor de anilina muito baixo | |
| EP3845534A4 (en) | SALT FORM AND CRYSTALLINE FORM OF A NEW AZATRICYCLIC COMPOUND AND USE THEREOF | |
| CA3298336A1 (en) | Salt of thiazolopyrazine compound or crystal thereof and use thereof |